New York-based Kadmon Pharmaceuticals has been granted an exclusive license to three clinical-stage product candidates owned by Brighton, MA-based Nano Terra, according to a press release. Kadmon will also have rights to Nano Terra’s drug-discovery platform, and the two companies will form a joint venture called NT Life Sciences. The three drug candidates target specific enzymes and are currently being studied in several diseases, including metabolic syndrome, diabetes, and spinal cord injury. “This transaction brings to Kadmon remarkably well-developed clinical compounds targeting important pathways of disease as well as a powerful discovery engine,” said Samuel D. Waksal, Ph.D., CEO of Kadmon, in a statement. The terms of the agreement were not disclosed.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
